Share Name Share Symbol Market Type Share ISIN Share Description
Hutchison China Meditech LSE:HCM London Ordinary Share KYG4672N1016 ORD USD1
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +25.00p +0.54% 4,675.00p 4,650.00p 4,700.00p 4,700.00p 4,650.00p 4,650.00p 5,475 14:00:17
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 178.6 -39.6 -31.8 - 2,840.07

Hutchison China Meditech Share Discussion Threads

Showing 1476 to 1499 of 1500 messages
Chat Pages: 60  59  58  57  56  55  54  53  52  51  50  49  Older
DateSubjectAuthorDiscuss
23/4/2018
07:55
Thanks nerd, I may try to go, other commitments allowing.
mad foetus
22/4/2018
09:32
hi mad, yes, going to the AGM, I think this will be my 6th or 7th year of attendance. The nice thing about the meeting is very few Private Shareholders attend, usually 3 or 4 at the most, so it gives you a good opportunity to talk to Board members and senior management directly. The CEO usually does a short presentation, based on the latest Co. one on the website, and is happy to answer non-material questions.
nerdofsteel
22/4/2018
07:15
Also, any of you guys going to the AGM and/or if you have before would you recommend it? I'm just about free on Friday.
mad foetus
22/4/2018
07:00
Thanks Lauders, and it does seem everything is on track. It is just frustrating how long these trials take a what a gestation period it is from concept to launch. Nature of the beast I know.
mad foetus
22/4/2018
02:31
For those, like me, who like a record of things stated about HCM progress by other companies. Here are the relevant excerpts from the AZ report that NofS mentioned: 1 - “2017 was a pivotal year for Oncology, with important data readouts for osimertinib, olaparib, durvalumab and acalabrutinib. We made exciting progress with combinations: olaparib with other agents from our DNA damage response (DDR) portfolio, savolitinib with osimertinib, and AZD9150, our antisense oligonucleotide (ASO) signal transducer and activator of transcription 3 (STAT3) inhibitor, with durvalumab. In addition, we moved our cell death portfolio into the clinic. Translational science has been critical to these developments and is helping to ensure we treat patients who are most likely to benefit from our innovative approaches.” Susan Galbraith, Vice President, Head of IMED Oncology 2 - We progressed evaluation of savolitinib in collaboration with our Global Medicines Development (GMD) colleagues, by continued enrolment in a clinical study in c-MET-driven EGFR mutation positive non-small cell lung cancer (NSCLC), combining savolitinib with osimertinib in the TATTON trial and completing enrolment with gefitinib in a trial in China. Initiation of these studies was based on strong science highlighting the co-dependence on both c-MET and EGFR in some cancers and the potential for combining inhibitors targeting both of these receptor tyrosine kinases in a subset of patients with lung cancer. Clinical data were presented at the World Congress on Lung Cancer in Japan in 2017. A Phase III investment decision was made in 2016 for c-MET-driven papillary renal cell cancer (PRCC). Initiation of the Phase III trial in PRCC occurred in 2017, with enrolment ongoing. Savolitinib monotherapy continues to be explored in Phase I/II studies in other cancers, including stomach, kidney and lung, and in combination with durvalumab, a programmed death-ligand 1 (PD-L1) antibody, in kidney cancer. 3 - Savolitinib: a highly selective small molecule inhibitor of c-MET, partnered with Hutchison Pharma, is being evaluated in c-MET-driven cancers. It is currently in a confirmatory Phase III trial in PRCC, is also being evaluated in a Phase II trial in patients with a certain type of lung cancer.
lauders
21/4/2018
09:32
Upside is hcm has more potential over medium and longer Term. It’s a real investment not a takeover punt.
dbadvn
21/4/2018
08:31
true......unfortunately, and that has always put off American retail investors, who are looking for the next Juno or Pharmacyclics type deal by big Pharma with their patent cliffs...........
nerdofsteel
20/4/2018
16:10
But.....HCM is bid proof
steeplejack
19/4/2018
11:51
should pick-up in the US NASDAQ market as well, when it opens.
nimrod22
19/4/2018
11:31
Rumours of Takada making an offer for Shire. Sector could get hot imo
mad foetus
19/4/2018
11:01
Savolitinib gets plenty of coverage in AZN's annual review just published + Chi-Med detailed as partner hxxps://www.astrazeneca.com/content/dam/az/PDF/2017/IMED_Annual%20Review%202017_FINAL%20APPROVED.pdf#page=6
nerdofsteel
19/4/2018
09:06
Looks like it has but it will be great to see the US reaction as well
mad foetus
19/4/2018
07:48
Will be interesting to see if the news from AZN has any positive influence on HCM today.
lauders
18/4/2018
07:18
thanks Lauders, I am in regular contact with Brad Loncars and alerted him to Chi-Med late last year. He is very bullish on Chinese Biotech.
nerdofsteel
17/4/2018
03:08
While we wait for news here is a fairly recent piece on the Loncar Index from Xinhuanet: Http://www.xinhuanet.com/english/2018-03/17/c_137045318.htm World's first global index on China's biopharma industry launched in U.S. EDIT - Will the 6.8% growth expectations for China announced today and which beat forecasts be good for HCM? Hopefully a Chinese news related positive day here. Https://www.nytimes.com/2018/04/16/business/china-economy-trade-gap-united-states-grows.html
lauders
16/4/2018
14:31
The trades at 1425 hrs & 1426 hrs are both buys
nimrod22
13/4/2018
09:46
great find, thankyou nimrod, glad to see Brad Loncar has woken up to the huge potential in China and has even created his own Index
nerdofsteel
12/4/2018
04:10
Good article in the FT re cancer treatment in China https://www.ft.com/content/30b5a944-3b57-11e8-b9f9-de94fa33a81e?emailId=5acde9bbf10cbb0004ce74d3&;segmentId=13b7e341-ed02-2b53-e8c0-d9cb59be8b3b
nimrod22
11/4/2018
08:21
very wise DB.....NDA by CFDA coming shortly, let's hope the priority review process works as intended...
nerdofsteel
10/4/2018
20:18
At this level i am buying for the first time in 4 years..
dbadvn
04/4/2018
12:08
Good to hear that Nerd. This event will be like manna from heaven :-)
thornyone
04/4/2018
11:04
in response to your No. 1385 thorny, the CFDA now take no longer than the U.S. FDA in terms of granting the NDA approval. They also have a fast track process, which we are using. The Company fully espects approval in the next few months.
nerdofsteel
04/4/2018
10:16
Interesting chart analysis haydock and fairly convincing. So he's saying a possible brief recovery to around £48 then a resumption of the downtrend to around £33 before a possible slow recovery. As you know technical analysis doesn't always play out and can be overshadowed by transformational news events. For example the anticipated Chinese government decision to approve a licence to market. 5 NASDAQ analysts apparently don't agree with the chart analysis either. Time will tell.
reptile3
04/4/2018
09:06
https://uk.advfn.com/cmn/fbb/thread.php3?id=40296935 Bikwik has kindly done extensive charting on HCM. Suggest well worth a look.
haydock
Chat Pages: 60  59  58  57  56  55  54  53  52  51  50  49  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180425 05:09:46